{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:50:07Z","timestamp":1782471007319,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["957777"],"award-info":[{"award-number":["957777"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Leishmaniasis is a serious health problem in some parts of the world. In spite of the many known leishmaniasis control measures, the disease has continued to increase in endemic areas, and no effective vaccine has been discovered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study,<jats:italic>Leishmania tarentulae<\/jats:italic>was used as a living factory for the production of two LACK and KMP11 immunogenic antigens in the mice body, and safety profiles were investigated. The sequences of the KMP11 and LACK<jats:italic>L. major<\/jats:italic>antigens were synthesized in the pLEXSY-neo 2.1 plasmid and cloned into<jats:italic>E. coli<\/jats:italic>strain Top10, and after being linearized with\u00a0the<jats:italic>SwaI<\/jats:italic>enzyme, they were transfected into the genome of<jats:italic>L. tarentolae<\/jats:italic>. The<jats:italic>L. tarentolae-LACK\/KMP11\/EGFP<\/jats:italic>in the stationary phase with CpG ODN as an adjuvant was used for vaccination in BALB\/c mice. Vaccination was performed into the left footpad. Three weeks later, the booster was injected in the same manner. To examine the effectiveness of the injected vaccine, pathogenic<jats:italic>L. major<\/jats:italic>(MRHO\/IR\/75\/ER) was injected into the right footpad of all mice three weeks following the booster vaccination. In order to assess humoral immunity, the levels of IgG1, and IgG2a antibodies before and 6 weeks after the challenge were studied in the groups. In addition, in order to investigate cellular immunity in the groups, the study measured IFN-\u03b3, IL-5, TNF-\u03b1, IL-6 and IL-17 cytokines before, 3 weeks and 8 weeks after the challenge, and also the parasite load in the lymph node with real-time PCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The lowest level of the\u00a0parasitic load was observed in the G1 group (mice vaccinated with<jats:italic>L. tarentolae-LACK\/KMP11\/EGFP<\/jats:italic>with CpG) in comparison with other groups (<jats:italic>L. tarentolae<\/jats:italic>-LACK\/KMP11\/EGFP +non-CpG (G2);<jats:italic>L. tarentolae<\/jats:italic>-EGFP + CpG (G3, control);<jats:italic>L. tarentolae<\/jats:italic>-EGFP + non-CpG (G4, control); and mice injected with PBS (G5, control). Moreover, the evaluation of immune response showed a delayed-type hypersensitivity towards Th1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>According to the results of this study, the live recombinant vaccine of<jats:italic>L. tarentolae-LACK\/KMP11\/EGFP<\/jats:italic>with the\u00a0CpG adjuvant reduced the parasitic load and footpad induration in infected mice. The long-term effects of this vaccine can be evaluated in volunteers as a clinical trial in future planning.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13071-020-04289-7","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T14:02:33Z","timestamp":1597240953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB\/c mice"],"prefix":"10.1186","volume":"13","author":[{"given":"Samira","family":"Salari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraj","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Reza","family":"Keyhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooya","family":"Ghasemi Nejad Almani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"4289_CR1","first-page":"521","volume-title":"Surveillance of leishmaniasis in the WHO European Region, 2016 and Global leishmaniasis surveillance update, 1998\u20132016","author":"WHO","year":"2018","unstructured":"WHO. Surveillance of leishmaniasis in the WHO European Region, 2016 and Global leishmaniasis surveillance update, 1998\u20132016, vol. 40. Geneva: World Health Organization; 2018. p. 521\u201340."},{"key":"4289_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.micpath.2018.04.053","volume":"121","author":"A Askari","year":"2018","unstructured":"Askari A, Sharifi I, Aflatoonian M, Babaei Z, Almani PGN, Mohammadi M, et al. A newly emerged focus of zoonotic cutaneous leishmaniasis in South-Western Iran. Microb Pathog. 2018;121:363\u20138.","journal-title":"Microb Pathog."},{"key":"4289_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/20477724.2018.1447836","volume":"112","author":"M Ramezany","year":"2018","unstructured":"Ramezany M, Sharifi I, Babaei Z, Ghasemi Nejad Almani P, Heshmatkhah A, Keyhani A, et al. Geographical distribution and molecular characterization for cutaneous leishmaniasis species by sequencing and phylogenetic analyses of kDNA and ITS1 loci markers in south-eastern Iran. Pathog Glob Health. 2018;112:132\u201341.","journal-title":"Pathog Glob Health."},{"key":"4289_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.actatropica.2015.10.025","volume":"154","author":"PG Almani","year":"2016","unstructured":"Almani PG, Sharifi I, Kazemi B, Babaei Z, Bandehpour M, Salari S, et al. The role of GlcNAc-PI-de-N-acetylase gene by gene knockout through homologous recombination and its consequences on survival, growth and infectivity of Leishmania major in in vitro and in vivo conditions. Acta Trop. 2016;154:63\u201372.","journal-title":"Acta Trop."},{"key":"4289_CR5","first-page":"448","volume":"11","author":"PGN Almani","year":"2016","unstructured":"Almani PGN, Sharifi I, Kazemi B, Babaei Z, Bandehpour M, Salari S, et al. Designing and cloning molecular constructs to knock out N-acetylglucosamine phosphatidylinositol De-N-acetylase (GPI12) gene in Leishmania major (MRHO\/IR\/75\/ER). Iran J Parasitol. 2016;11:448.","journal-title":"Iran J Parasitol."},{"key":"4289_CR6","doi-asserted-by":"publisher","first-page":"e0007423","DOI":"10.1371\/journal.pntd.0007423","volume":"13","author":"MR Aflatoonian","year":"2019","unstructured":"Aflatoonian MR, Sharifi I, Aflatoonian B, Bamorovat M, Heshmatkhah A, Babaei Z, et al. Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: a cohort study in Iran. PLoS Negl Trop Dis. 2019;13:e0007423.","journal-title":"PLoS Negl Trop Dis."},{"key":"4289_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2010.06.023","volume":"36","author":"JAR Postigo","year":"2010","unstructured":"Postigo JAR. Leishmaniasis in the World Health Organization Eastern Mediterranean Region. Int J Antimicrob Agents. 2010;36:62\u20135.","journal-title":"Int J Antimicrob Agents."},{"key":"4289_CR8","first-page":"291","volume":"23","author":"MR Yaghoobi-Ershadi","year":"2002","unstructured":"Yaghoobi-Ershadi MR, Hanafi-Bojd AA, Javadian E, Jafari R, Zahraei-Ramazani AR, Mohebali M. A new focus of cutaneous leishmaniasis caused by Leishmania tropica. Saudi Med J. 2002;23:291.","journal-title":"Saudi Med J."},{"key":"4289_CR9","unstructured":"Nadim A, Tahvildari Bidruni G, Tahvildari Bidruni G. Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan. Part VI: cutaneous leishmaniasis in Neishabur, Iran. Bull Soc Pathol Exot. 1977:171."},{"key":"4289_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"SLSS Croft","year":"2006","unstructured":"Croft SLSS, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111\u201326.","journal-title":"Clin Microbiol Rev."},{"key":"4289_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaad.2007.01.016","volume":"57","author":"AFA Khatami","year":"2007","unstructured":"Khatami AFA, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol. 2007;57:335.","journal-title":"J Am Acad Dermatol."},{"key":"4289_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1126\/science.7725103","volume":"268","author":"EAF Mougneau","year":"1995","unstructured":"Mougneau EAF, Wakil AE, Zheng S, Coppola T, Wang ZE, Waldmann R, Locksley RM, Glaichenhaus N. Expression cloning of a protective Leishmania antigen. Science. 1995;268:563\u20136.","journal-title":"Science."},{"key":"4289_CR13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","volume":"186","author":"S Gurunathan","year":"1997","unstructured":"Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med. 1997;186:1137\u201347.","journal-title":"J Exp Med."},{"key":"4289_CR14","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1128\/IAI.70.6.3122-3129.2002","volume":"70","author":"E Bourreau","year":"2002","unstructured":"Bourreau E, Prevot G, Gardon J, Pradinaud R, Hasagewa H, Milon G, et al. LACK-specific CD4(+) T cells that induce gamma interferon production in patients with localized cutaneous leishmaniasis during an early stage of infection. Infect Immun. 2002;70:3122\u20139.","journal-title":"Infect Immun."},{"key":"4289_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1086\/315725","volume":"182","author":"K Maasho","year":"2000","unstructured":"Maasho K, Satti I, Nylen S, Guzman G, Koning F, Akuffo H. A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-gamma and interleukin-10 in natural killer cells of healthy blood donors. J Infect Dis. 2000;182:570\u20138.","journal-title":"J Infect Dis."},{"key":"4289_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1042\/bj3050315","volume":"305","author":"A Jardim","year":"1995","unstructured":"Jardim A, Hanson S, Ullman B, McCubbin WD, Kay CM, Olafson RW. Cloning and structure-function analysis of the Leishmania donovani kinetoplastid membrane protein-11. Biochem J. 1995;305:315\u201320.","journal-title":"Biochem J."},{"key":"4289_CR17","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00436-018-5915-6","volume":"117","author":"N Mortazavidehkordi","year":"2018","unstructured":"Mortazavidehkordi N, Fallah A, Abdollahi A, Kia V, Khanahmad H, Najafabadi ZG, et al. A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB\/C. Parasitol Res. 2018;117:2265\u201373.","journal-title":"Parasitol Res."},{"key":"4289_CR18","doi-asserted-by":"publisher","first-page":"O6","DOI":"10.1186\/1753-6561-5-S1-O6","volume":"5","author":"S Rafati","year":"2011","unstructured":"Rafati S, Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Papadopoulou B. Novel strategy using live non-pathogenic Leishmania expressing selected parasite antigens as a candidate vaccine for leishmaniasis. BMC Proc. 2011;5:O6.","journal-title":"BMC Proc."},{"key":"4289_CR19","doi-asserted-by":"publisher","first-page":"6372","DOI":"10.1128\/IAI.73.10.6372-6382.2005","volume":"73","author":"M Breton","year":"2005","unstructured":"Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun. 2005;73:6372\u201382.","journal-title":"Infect Immun."},{"key":"4289_CR20","doi-asserted-by":"publisher","first-page":"e2751","DOI":"10.1371\/journal.pntd.0002751","volume":"8","author":"F Zahedifard","year":"2014","unstructured":"Zahedifard F, Gholami E, Taheri T, Taslimi Y, Doustdari F, Seyed N, et al. Enhanced protective efficacy of nonpathogenic recombinant Leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen. PLoS Negl Trop Dis. 2014;8:e2751.","journal-title":"PLoS Negl Trop Dis."},{"key":"4289_CR21","doi-asserted-by":"crossref","unstructured":"Lachaud L M-HS, Chabbert E, Dereure J, Dedet JP, Bastien P. Comparison of six PCR methods using peripheral blood for detection of canine visceral leishmaniasis. J Clin Microbiol. 2002;40:210\u20135.","DOI":"10.1128\/JCM.40.1.210-215.2002"},{"key":"4289_CR22","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/eji.201040484","volume":"40","author":"W Wu","year":"2010","unstructured":"Wu W, Huang L, Mendez S. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL\/6 mice. Eur J Immunol. 2010;40:2517\u201327.","journal-title":"Eur J Immunol."},{"key":"4289_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/tmi.13062","volume":"23","author":"RT Oliaee","year":"2018","unstructured":"Oliaee RT, Sharifi I, Afgar A, Kareshk AT, Asadi A, Heshmatkhah A, et al. Unresponsiveness to meglumine antimoniate in anthroponotic cutaneous leishmaniasis field isolates: analysis of resistance biomarkers by gene expression profiling. Trop Med Int Health. 2018;23:622\u201333.","journal-title":"Trop Med Int Health."},{"key":"4289_CR24","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.4049\/jimmunol.162.4.2291","volume":"162","author":"KL Elkins","year":"1999","unstructured":"Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol. 1999;162:2291\u20138.","journal-title":"J Immunol."},{"key":"4289_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.molimm.2015.08.001","volume":"67","author":"A Katebi","year":"2015","unstructured":"Katebi A, Gholami E, Taheri T, Zahedifard F, Habibzadeh S, Taslimi Y, et al. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB\/c mice model. Mol Immunol. 2015;67:501\u201311.","journal-title":"Mol Immunol."},{"key":"4289_CR26","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.4049\/jimmunol.173.8.5148","volume":"173","author":"JC Deng","year":"2004","unstructured":"Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol. 2004;173:5148\u201355.","journal-title":"J Immunol."},{"key":"4289_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1574-695X.2009.00607.x","volume":"57","author":"R Kumar","year":"2009","unstructured":"Kumar R, Bumb R, Salotra P, Salotra P. Correlation of parasitic load with interleukin-4 response in patients with cutaneous leishmaniasis due to Leishmania tropica. FEMS Immunol Med Microbiol. 2009;57:239.","journal-title":"FEMS Immunol Med Microbiol."},{"key":"4289_CR28","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1128\/IAI.73.8.4948-4954.2005","volume":"73","author":"B Flynn","year":"2005","unstructured":"Flynn B, Wang V, Sacks DL, Seder RA, Verthelyi D. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D\/A oligodeoxynucleotides expressing CpG motifs. Infect Immun. 2005;73:4948\u201354.","journal-title":"Infect Immun."},{"key":"4289_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00005-008-0010-9","volume":"56","author":"R Silvestre","year":"2008","unstructured":"Silvestre R, Cordeiro-da-Silva A, Ouaissi A. Live attenuated Leishmania vaccines: a potential strategic alternative. Arch Immunol Ther Exp. 2008;56:123\u20136.","journal-title":"Arch Immunol Ther Exp."},{"key":"4289_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","volume":"14","author":"E Handman","year":"2001","unstructured":"Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev. 2001;14:229\u201343.","journal-title":"Clin Microbiol Rev."},{"key":"4289_CR31","doi-asserted-by":"publisher","first-page":"e1000484","DOI":"10.1371\/journal.ppat.1000484","volume":"5","author":"NC Peters","year":"2009","unstructured":"Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, Sacks DL. Vector transmission of Leishmania abrogates vaccine-induced protective immunity. PLoS Pathog. 2009;5:e1000484.","journal-title":"PLoS Pathog."},{"key":"4289_CR32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2015.00524","volume":"6","author":"SC de Mendonca","year":"2015","unstructured":"de Mendonca SC, Cysne-Finkelstein L, Matos DC. Kinetoplastid membrane protein-11 as a vaccine candidate and a virulence factor in Leishmania. Front Immunol. 2015;6:524.","journal-title":"Front Immunol."},{"key":"4289_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0264-410X(01)00341-3","volume":"20","author":"JR Ramirez","year":"2001","unstructured":"Ramirez JR, Gilchrist K, Robledo S, Sepulveda JC, Moll H, Soldati D, et al. Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB\/c mice. Vaccine. 2001;20:455\u201361.","journal-title":"Vaccine."},{"key":"4289_CR34","doi-asserted-by":"publisher","first-page":"e30945","DOI":"10.1371\/journal.pone.0030945","volume":"7","author":"FYK Hugentobler","year":"2012","unstructured":"Hugentobler FYK, Gillard J, Mahbuba R, Olivier M, Cousineau B. Immunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swelling. PLoS One. 2012;7:e30945.","journal-title":"PLoS One."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-020-04289-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:21:50Z","timestamp":1696526510000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-04289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4289"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-04289-7","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"28 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments on laboratory animals were performed in accordance with the guideline for research on laboratory animals, approved by the Ethics Committee of the Ministry of Health and Medical Education of I. R. Iran. The steps of the study were approved by the Ethics Committee of the National Institute for Medical Research Development (Ethics Code: IR. NIMAD.REC.1396.064).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"415"}}